Theorem Clinical Research

Drug Sponsors

StemTech to open Florida facility, hire 90

Wednesday, March 19, 2014 12:55 PM

Stemtech International, a stem cell technology company, will move its headquarters from San Clemente, Calif., to Pembroke Pines, Fla., creating 90 jobs.

More... »

Teva, NIHR form health research collaboration

Wednesday, March 19, 2014 12:50 PM

Israeli pharmaceutical company Teva will invest $20 million into U.K. clinical trials and $1 million into U.K. dementia research. Teva said it will benefit from the NIHR's translational research infrastructure and its ability to efficiently set up and deliver world-leading health research studies.

More... »

SillaJen completes Jennerex acquisition

Monday, March 17, 2014 01:44 PM

SillaJen, a privately held biotherapeutics company focused on the development of targeted oncolytic immunotherapy products for cancer, has completed the acquisition of San Francisco-based Jennerex. Privately held Jennerex is a clinical-stage, biotherapeutics company developing best-in-class targeted oncolytic immunotherapies.

More... »

Vectura Group acquires Activaero

Monday, March 17, 2014 01:38 PM

Vectura, a product development company that focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases, has acquired Activaero, a private German pharmaceutical company focused on the development of products for the treatment of respiratory diseases, for $179.6 million, to be funded through a combination of existing cash and equity.

More... »

AstraZeneca sells Alderley Park site in Cheshire, U.K.

Wednesday, March 12, 2014 01:41 PM

AstraZeneca has sold its Alderley Park site in Cheshire, U.K., to Manchester Science Parks(MSP), a Greater Manchester-based public-private partnership and science park operator.

More... »

Intrexon completes acquisition of MediStem

Monday, March 10, 2014 11:50 AM

Intrexon, a provider of synthetic biology, has completed the acquisition of San Diego-based Medistem, a pioneer in the development of Endometrial Regenerative Cells (ERCs), universal donor adult-derived stem cells with properties uniquely suited for therapeutic use with Intrexon's existing suite of synthetic biology technologies.

More... »

Stratus Media Group acquires Paloma Pharmaceuticals and VasculoMedics

Monday, March 10, 2014 11:48 AM

Stratus Media Group (SMDI) has announced the acquisition, through merger, of two biotechnology companies, Paloma Pharmaceuticals, a developer of a non-steroidal, synthetic, small molecule drug library, and VasculoMedics, a platform epigenetic company that develops orally available small molecular inhibitors of zinc finger transcription factors.

More... »

NanoViricides denies $4.5B acquisition rumor

Monday, March 10, 2014 11:45 AM

NanoViricides, a development stage company creating special purpose nanomaterials for viral therapy, has denied a statement made in a blog post on the Seeking Alpha web site that it is being acquired for $2.25 billion to $4.5 billion.

More... »

TNI BioTech forms new subsidiary Cytocom

Thursday, March 6, 2014 03:58 PM

TNI BioTech, a biotech company working on chronic, life-threatening diseases, has formed a new subsidiary, Cytocom, for developing Low Dose Naltrexone (LDN) and Met-enkephalin (MENK).

More... »

Xenetic Biosciences opens headquarters, R&D facility

Wednesday, March 5, 2014 01:19 PM

Xenetic Biosciences, a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, has opened its new corporate headquarters and R&D facility in Lexington, Mass. Xenetic relocated its global headquarters to Lexington from London.

More... »

Subscribe to The CenterWatch Monthly



Browse by:


October 27

NIH’s I-Corps boot camp aims to transform researchers into better businesspeople before they launch products

Covance, Frenova form partnership to share patient databases, find effective treatments for renal disease

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs